455 results on '"Jäger, Ulrich"'
Search Results
2. Author Correction: Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study
3. Daratumumab monotherapy in refractory warm autoimmune hemolytic anemia and cold agglutinin disease
4. Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study
5. Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with r/r DLBCL: phase 1b PORTIA study results
6. Management of Cytokine Release Syndrome (CRS) and HLH
7. Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study
8. Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab
9. Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma
10. Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL
11. EHA evaluation of the ESMO—Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies
12. Lymphodepletion – an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle
13. Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia
14. UGT2B17 modifies drug response in chronic lymphocytic leukaemia
15. Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial
16. The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL
17. CD44 is a RAS/STAT5-regulated invasion receptor that triggers disease expansion in advanced mastocytosis
18. A chimeric antigen receptor-based cellular safeguard mechanism for selective in vivo depletion of engineered T cells.
19. Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations
20. Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy
21. Phenotyping and Target Expression Profiling of CD34+/CD38− and CD34+/CD38+ Stem- and Progenitor cells in Acute Lymphoblastic Leukemia
22. Short telomeres are associated with inferior outcome, genomic complexity, and clonal evolution in chronic lymphocytic leukemia
23. Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma
24. Sustained hematologic remission after discontinuation of sutimlimab treatment in patients with cold agglutinin disease
25. Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL
26. The Human GRAF Gene Is Fused to MLL in a Unique t(5;11)(q31;q23) and Both Alleles Are Disrupted in Three Cases of Myelodysplastic Syndrome/Acute Myeloid Leukemia with a Deletion 5q
27. The frequency of differentiated CD3+CD27-CD28- T cells predicts response to CART cell therapy in diffuse large B-cell lymphoma
28. N‐terminal pro‐brain natriuretic peptide is a prognostic marker for response to intensive chemotherapy, early death, and overall survival in acute myeloid leukemia
29. Simplified Fabrication of n-type Cz-Si HIP-MWT+ Solar Cells with 20% Efficiency Using Laser Structuring
30. Deep Morphology Learning Enhances Ex Vivo Drug Profiling-Based Precision Medicine
31. Long-Term Host Immune Changes Following Treatment with Venetoclax Plus Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia
32. Stringent Nationwide Selection Criteria for CAR-T Cell Therapy Ensure Favourable Outcome of Patients with LBCL - First Data from the Austrian CAR-T Network
33. YTB323 (Rapcabtagene Autoleucel) Demonstrates Durable Efficacy and a Manageable Safety Profile in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Phase I Study Update
34. Abstract 5186: Higher levels of circulating exhausted T-cells at pre- and post-infusion negatively associated with clinical efficacy in tisagenlecleucel (Tisa-cel) treated relapsed/refractory large B-cell lymphoma (r/r LBCL) patients (pts) in JULIET trial
35. Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma
36. Recombinant antibodies encoded by IGHV1-69 react with pUL32, a phosphoprotein of cytomegalovirus and B-cell superantigen
37. The cancer survival index—A prognostic score integrating psychosocial and biological factors in patients diagnosed with cancer or haematologic malignancies
38. How I manage autoimmune cytopenias in patients with lymphoid cancer
39. Der Zusammenhang von interpersonalen Subtypen und der Veränderung interpersonaler Probleme am Beispiel stationärer Psychotherapiepatienten
40. Comprehensive Characterization of Advanced Cell Concepts with Sub-Micron Resolution
41. Quantum Efficiency Analysis of Highly Doped Areas for Selective Emitter Solar Cells
42. Zur Wirksamkeit psychoanalytisch-interaktioneller Therapie am Beispiel der Borderline-Persönlichkeitsstörung: Daten aus der klinischen Praxis
43. Ergebnisse stationärer psychiatrischer und psychotherapeutischer Behandlung von schizophrenen, schizoaffektiven und anderen psychotischen Störungen
44. Reconstitution of PTEN activity by CK2 inhibitors and interference with the PI3-K/Akt cascade counteract the antiapoptotic effect of human stromal cells in chronic lymphocytic leukemia
45. How I treat autoimmune hemolytic anemias in adults
46. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma
47. Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance
48. Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma
49. Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia
50. Precision Medicine in Hematology 2021: Definitions, Tools, Perspectives, and Open Questions
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.